Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 4/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22761804 | 0.81 | LTA4H (0.57) | LTA4H | |
| SCHEMBL10121582 | 0.79 | HPGD (0.38) | LIPELTA4HHPGDGABRA5MAPK1 | |
| SCHEMBL6523847 | 0.77 | NPC1 (0.41) | HCRTR1 | |
| SCHEMBL19207136 | 0.73 | HPGD (0.38) | LIPEHPGDGABRA5MAPK1HCRTR1 | |
| SCHEMBL31424098 | 0.72 | LIPE (0.35) | LIPE | |
| SCHEMBL21606958 | 0.72 | EP300 (0.51) | LIPE | |
| SCHEMBL31424097 | 0.72 | LIPE (0.35) | LIPE | |
| SCHEMBL20774314 | 0.72 | HCRTR1 (0.41) | LIPEHPGDGABRA5MAPK1HCRTR1 | |
| SCHEMBL9900511 | 0.72 | HCRTR1 (0.37) | HCRTR1 | |
| SCHEMBL15229796 | 0.72 | LTA4H (0.39) | LIPELTA4HHPGDHCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470523-A1 | 5-METHYL-PIPERIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP DISORDER | Glaxo Group Limited (GB) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149723-A1 | 5-METHYL-PIPERIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP DISORDER | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | US | disclosed |
| US-20120149723-A1 | 5-METHYL-PIPERIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP DISORDER | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | US | disclosed |
| US-20120149723-A1 | 5-METHYL-PIPERIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP DISORDER | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149723-A1 | 5-METHYL-PIPERIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP DISORDER | HCRTR2, HCRTR1, HTR5A | LIPE 2454/4885LTA4H 1392/4885HPGD 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.